Analytical Evaluation of the New Prostatus™ PSA Free/Total Assay for Prostate-Specific Antigen as Part of a Screening Study for Prostate Cancer

European Journal of Clinical Chemistry and Clinical Biochemistry

Volumn 35, Issue 2, 1997, Pages 111-114

  Blijenberg, Bert G ^a   Bangma, Chris H ^a   Kranse, Ries ^a   Eman, Ineke ^a   Schröder, Fritz H ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ACCURACY; ADULT; AGE; AGED; ANALYTIC METHOD; ARTICLE; BLOOD LEVEL; CANCER SCREENING; CONTROLLED STUDY; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY;

ADULT; AGE FACTORS; AGED; EVALUATION STUDIES; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REAGENT KITS, DIAGNOSTIC; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY;

EID: 0030889515     PISSN: 09394974     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Stenman UH, Leionen J, Alfthan H, Rannikko S, Tuhkanen A, Alfthan U. A complex between PSA and alpha-1-anti-chymotrypsin is the major form of PSA in serum of patients with prostate cancer: assay of the complex improves the clinical sensitivity for cancer. Cancer Res 1991; 51:222-6.
2. Lilja H, Christensson A, Dahlen U, Martikainen MT, Nillsson O, Pettersson K, Lövgren T. Prostate-specific antigen in serum occurs predominantly in complex with alpha-1-antichymotrypsin. Clin Chem 1991; 37:1618-25.
3. Mitrunen K, Pettersson K, Piironen T, Bjork T, Lilja H, Tövgren T. Dual-label one-step immunoassay for simultaneous measurement of free and total prostate-specific antigen concentrations and ratios in serum. Clin Chem 1995; 41:1115-20.
4. Leinonen J, Lövgren T, Vornanen T, Stenman UH. Dual-label time-resolved immunofluorometric assay of prostate-specific antigen and of its complex with dpanti-chymotrypsin. Clin Chem 1993; 39:2098-103.
5. Schröder FH, Damhuis RAM, Kirkels WJ, De Koning HJ, Kranse R, Nijs HOT, Blijenberg BG. European randomized study of screening for prostate cancer -the Rotterdam Pilot Studies. Int J Cancer 1996; 65:145-51.
6. Bangma CH, Kranse R, Blijenberg BG, Schröder FH. The value of screening tests in the detection of prostate cancer. Part 1: results of a retrospective evaluation of 1726 men. Urology 1995; 46:773-8.
7. Bangma CH, Kranse R, Blijenberg BG, Schröder FH. The value of screening tests in the detection of prostate cancer. Part 2: retrospective analysis of free/total prostate-specific analysis ratio, age-specific reference ranges and PSA density. Urology 1995; 46:779-84.
8. Suonpää M, Pettersson K, Piironen T, Lövgren T, Reisto T, Lilja H. A simultaneous Autodelfia™ dual-label assay for free/
9. th International European Congress of Clinical Chemistry 1995: Tampere, Finland. Scand J Clin Lab Invest 1995; 55 (Suppl 223):750.
10. th International European Congress of Clinical Chemistry 1995: Tampere, Finland. Scand J Clin Lab Invest 1995; 55 (Suppl 223):763.
11. Passing H, Bablok W. A new biomedical procedure for testing the equality of measurements from two different analytical methods. J Clin Chem Clin Biochem 1983; 21:709-20.
12. Oesterling JE, Jacobsen SJ. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. J Am Med Ass 1994; 270:860-4.
13. Oesterling JE, Jacobsen SJ, Klee GG, Pettersson K, Piironen T, Abrahamsson PA, et al. Free, complexed and total serum prostate-specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. J Urol 1995; 154:1090-5.
14. Brawer MK, Daum P, Petteway JC, Wener MH. Assay variability in serum prostate-specific antigen determination. Prostate 1995; 27:1-6.